CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+17.85%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$709M
AUM Growth
+$709M
(+25%)
Cap. Flow
+$90.2M
Cap. Flow
% of AUM
12.73%
Top 10 Holdings %
Top 10 Hldgs %
61.15%
Holding
35
New
4
Increased
10
Reduced
4
Closed
2
Top Buys
| 1 |
Dianthus Therapeutics
DNTH
|
$27.5M |
| 2 |
FMI
Foundation Medicine, Inc.
FMI
|
$22.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$18.2M |
| 4 |
BioLife Solutions
BLFS
|
$11.4M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$10.9M |
Top Sells
| 1 |
Evolent Health
EVH
|
$11.8M |
| 2 |
iShares Biotechnology ETF
IBB
|
$10.1M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$5.42M |
| 4 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$2.87M |
| 5 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$1.99M |
Sector Composition
| 1 | Healthcare | 91.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
FMI
1
DELISTED
Foundation Medicine, Inc.
FMI
| $93.6M | 13.1% | 685,000 +165,000 | +32% | +$22.6M |
|
|
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
| $62.5M | 8.73% | 360,000 | – | – |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $40.3M | 5.64% | 635,000 +287,000 | +82% | +$18.2M |
|
|
SAGE
4
DELISTED
Sage Therapeutics
SAGE
| $39.1M | 5.47% | 250,000 | – | – |
|
|
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $38.7M | 5.42% | 780,000 +220,000 | +39% | +$10.9M |
|
|
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $38.3M | 5.36% | 463,000 | – | – |
|
|
BLUE
7
DELISTED
bluebird bio
BLUE
| $31.4M | 4.39% | 200,000 +55,000 | +38% | +$8.63M |
|
8
Agios Pharmaceuticals
AGIO
$2.19B
| $30.7M | 4.3% | 364,776 | – | – |
|
9
Fate Therapeutics
FATE
$120M
| $29.5M | 4.12% | 2,600,000 | – | – |
|
10
Codexis
CDXS
$246M
| $29.2M | 4.08% | 2,025,000 | – | – |
|
|
11
Dianthus Therapeutics
DNTH
$759M
| $27.5M | 3.84% | +2,035,818 | New | +$27.5M |
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $26.6M | 3.72% | 270,000 +20,000 | +8% | +$1.97M |
|
13
Voyager Therapeutics
VYGR
$186M
| $22.2M | 3.1% | 1,135,000 | – | – |
|
|
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $21.7M | 3.03% | 480,000 -120,000 | -20% | -$5.42M |
|
|
GNMK
15
DELISTED
GenMark Diagnostics, Inc
GNMK
| $21.7M | 3.03% | 3,400,000 -450,000 | -12% | -$2.87M |
|
16
Illumina
ILMN
$15.8B
| $20M | 2.79% | 71,500 | – | – |
|
17
Sangamo Therapeutics
SGMO
$157M
| $19.9M | 2.78% | 1,400,000 | – | – |
|
|
BOLD
18
DELISTED
Audentes Therapeutics, Inc
BOLD
| $17.2M | 2.4% | 450,000 | – | – |
|
19
CRISPR Therapeutics
CRSP
$4.71B
| $12.9M | 1.81% | 220,000 +85,000 | +63% | +$4.99M |
|
|
20
Evolent Health
EVH
$1.12B
| $11.6M | 1.62% | 550,000 -560,000 | -50% | -$11.8M |
|
|
21
BioLife Solutions
BLFS
$1.2B
| $11.4M | 1.6% | +1,000,000 | New | +$11.4M |
|
|
ONC
22
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $10.8M | 1.51% | 70,000 | – | – |
|
23
OraSure Technologies
OSUR
$242M
| $10.5M | 1.47% | 640,000 +400,000 | +167% | +$6.59M |
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| $10M | 1.4% | 220,000 +42,500 | +24% | +$1.93M |
|
25
Editas Medicine
EDIT
$231M
| $6.39M | 0.89% | 178,333 +45,000 | +34% | +$1.61M |
|